Impact of anemia on the outcomes of chronic phase chronic myeloid leukemia in TKI era

被引：12

作者：

Liu, Zhenyou ^{[1
]}

Shi, Yuye ^{[1
]}

Yan, Zhiling ^{[2
]}

He, Zhengmei ^{[1
]}

Ding, Banghe ^{[1
]}

Tao, Shandong ^{[1
]}

Li, Yunjie ^{[1
]}

Yu, Liang ^{[1
]}

Wang, Chunling ^{[1
]}

机构：

[1] Xuzhou Med Univ, Dept Hematol, Huaian Clin Coll, Huaian, Peoples R China

[2] Xuzhou Med Univ, Dept Hematol, Affiliated Hosp, Xuzhou, Jiangsu, Peoples R China

来源：

HEMATOLOGY | 2020年 / 25卷 / 01期

关键词：

Chronic myeloid leukemia; anemia; hemoglobin level; survival; prognosis; tyrosine kinase inhibitor; chronic phase; optimal response; IMATINIB TREATMENT; SURVIVAL; EUTOS; CML;

D O I：

10.1080/16078454.2020.1765563

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objectives: It is common of chronic phase chronic myeloid leukemia (CML-CP) patients coexisting anemia at diagnosis, but the role of anemia on the prognosis is not clear. This study aims to explore impact of anemia on outcomes of CML-CP patients in TKI era. Methods: In the retrospective study, 258 newly diagnosed CML patients treated with TKIs were enrolled. Patients with moderate anemia (Hb <= 90 g/L) and non-moderate anemia (Hb > 90 g/L) were compared. Results: The incidence of moderate anemia at the time of CML diagnosis was 34.8%. Compared with patients with non-moderate anemia, patients with moderate anemia had higher proportion of intermediate-high Sokal risks and more aggressive characteristics such as higher WBC counts, higher percent of myeloblasts and basophils. However, there were no statistical differences in terms of optimal response rates, 5-year PFS and OS between the two groups. Conclusion: Moderate anemia is a common concomitant symptom in CML-CP patients and is associated with high-risk CML, but its occurrence does not affect the survival of CML-CP patients in TKI era.

引用

页码：181 / 185

页数：5

共 9 条

[1] Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib [J].

Efficace, F. ;

Baccarani, M. ;

Breccia, M. ;

Cottone, F. ;

Alimena, G. ;

Deliliers, G. L. ;

Barate, C. ;

Specchia, G. ;

Di Lorenzo, R. ;

Luciano, L. ;

Turri, D. ;

Martino, B. ;

Stagno, F. ;

Dabusti, M. ;

Bergamaschi, M. ;

Leoni, P. ;

Simula, M. P. ;

Levato, L. ;

Fava, C. ;

Veneri, D. ;

Sica, S. ;

Rambaldi, A. ;

Rosti, G. ;

Vignetti, M. ;

Mandelli, F. .

LEUKEMIA, 2013, 27 (07) :1511-1519

[2] Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score [J].

Hasford, Joerg ;

Baccarani, Michele ;

Hoffmann, Verena ;

Guilhot, Joelle ;

Saussele, Susanne ;

Rosti, Gianantonio ;

Guilhot, Francois ;

Porkka, Kimmo ;

Ossenkoppele, Gert ;

Lindoerfer, Doris ;

Simonsson, Bengt ;

Pfirrmann, Markus ;

Hehlmann, Rudiger .

BLOOD, 2011, 118 (03) :686-692

[3] Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants [J].

Hehlmann, R. ;

Lauseker, M. ;

Saussele, S. ;

Pfirrmann, M. ;

Krause, S. ;

Kolb, H. J. ;

Neubauer, A. ;

Hossfeld, D. K. ;

Nerl, C. ;

Gratwohl, A. ;

Baerlocher, G. M. ;

Heim, D. ;

Bruemmendorf, T. H. ;

Fabarius, A. ;

Haferlach, C. ;

Schlegelberger, B. ;

Mueller, M. C. ;

Jeromin, S. ;

Proetel, U. ;

Kohlbrenner, K. ;

Voskanyan, A. ;

Rinaldetti, S. ;

Seifarth, W. ;

Spiess, B. ;

Balleisen, L. ;

Goebeler, M. C. ;

Haenel, M. ;

Ho, A. ;

Dengler, J. ;

Falge, C. ;

Kanz, L. ;

Kremers, S. ;

Burchert, A. ;

Kneba, M. ;

Stegelmann, F. ;

Koehne, C. A. ;

Lindemann, H. W. ;

Waller, C. F. ;

Pfreundschuh, M. ;

Spiekermann, K. ;

Berdel, W. E. ;

Mueller, L. ;

Edinger, M. ;

Mayer, J. ;

Beelen, D. W. ;

Bentz, M. ;

Link, H. ;

Hertenstein, B. ;

Fuchs, R. ;

Wernli, M. .

LEUKEMIA, 2017, 31 (11) :2398-2406

[4] Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia [J].

Hochhaus, Andreas ;

Larson, Richard A. ;

Guilhot, Francois ;

Radich, Jerald P. ;

Branford, Susan ;

Hughes, Timothy P. ;

Baccarani, Michele ;

Deininger, Michael W. ;

Cervantes, Francisco ;

Fujihara, Satoko ;

Ortmann, Christine-Elke ;

Menssen, Hans D. ;

Kantarjian, Hagop ;

O'Brien, Stephen G. ;

Druker, Brian J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (10) :917-927

[5] Moderate anemia at diagnosis is an independent prognostic marker of the EUTOS, Sokal, and Hasford scores for survival and treatment response in chronic-phase, chronic myeloid leukemia patients with frontline imatinib [J].

Ko, Po-Shen ;

Yu, Yuan-Bin ;

Liu, Yao-Chung ;

Wu, Yi-Tsui ;

Hung, Man-Hsin ;

Gau, Jyh-Pyng ;

Liu, Chia-Jen ;

Hsiao, Liang-Tsai ;

Chena, Po-Min ;

Chiou, Tzeon-Jye ;

Liu, Chun-Yu ;

Liu, Jin-Hwang .

CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (10) :1737-1744

[6] The Prevalence of Anemia and Moderate-Severe Anemia in the US Population (NHANES 2003-2012) [J].

Le, Chi Huu Hong .

PLOS ONE, 2016, 11 (11)

[7] Alterations in the bone marrow microenvironment may elicit defective hematopoiesis: a comparison of aplastic anemia, chronic myeloid leukemia, and normal bone marrow [J].

Park, Meerim ;

Park, Chan-Jeoung ;

Cho, Young Wook ;

Jang, Seongsoo ;

Lee, Jung-Hee ;

Lee, Je-Hwan ;

Lee, Kyoo-Hyung ;

Lee, Young Ho .

EXPERIMENTAL HEMATOLOGY, 2017, 45 :56-63

[8] Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia [J].

Pfirrmann, M. ;

Baccarani, M. ;

Saussele, S. ;

Guilhot, J. ;

Cervantes, F. ;

Ossenkoppele, G. ;

Hoffmann, V. S. ;

Castagnetti, F. ;

Hasford, J. ;

Hehlmann, R. ;

Simonsson, B. .

LEUKEMIA, 2016, 30 (01) :48-56

[9] Chronic Myeloid Leukemia, Version 1.2019 Clinical Practice Guidelines in Oncology [J].

Radich, Jerald P. ;

Deininger, Michael ;

Abboud, Camille N. ;

Altman, Jessica K. ;

Berman, Ellin ;

Bhatia, Ravi ;

Bhatnagar, Bhavana ;

Curtin, Peter ;

DeAngelo, Daniel J. ;

Gotlib, Jason ;

Hobbs, Gabriela ;

Jagasia, Madan ;

Kantarjian, Hagop M. ;

Maness, Lori ;

Metheny, Leland ;

Moore, Joseph O. ;

Pallera, Arnel ;

Pancari, Philip ;

Patnaik, Mrinal ;

Purev, Enkhtsetseg ;

Rose, Michal G. ;

Shah, Neil P. ;

Smith, B. Douglas ;

Snyder, David S. ;

Sweet, Kendra L. ;

Talpaz, Moshe ;

Thompson, James ;

Yang, David T. ;

Gregory, Kristina M. ;

Sundar, Hema .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 (09) :1108-1135

← 1 →